vs
Side-by-side financial comparison of Entrada Therapeutics, Inc. (TRDA) and U-BX Technology Ltd. (UBXG). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $12.4M, roughly 1.7× U-BX Technology Ltd.). U-BX Technology Ltd. runs the higher net margin — -24.7% vs -84.4%, a 59.7% gap on every dollar of revenue.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
TRDA vs UBXG — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.6M | $12.4M |
| Net Profit | $-17.3M | $-3.1M |
| Gross Margin | — | 0.4% |
| Operating Margin | -106.0% | -22.1% |
| Net Margin | -84.4% | -24.7% |
| Revenue YoY | -65.2% | — |
| Net Profit YoY | -173.8% | — |
| EPS (diluted) | $-0.42 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $12.4M | ||
| Q1 25 | $20.6M | — | ||
| Q4 24 | $37.4M | — | ||
| Q3 24 | $19.6M | — | ||
| Q2 24 | $94.7M | — | ||
| Q1 24 | $59.1M | — | ||
| Q4 23 | $41.8M | — | ||
| Q3 23 | $43.7M | — |
| Q2 25 | — | $-3.1M | ||
| Q1 25 | $-17.3M | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | $55.0M | — | ||
| Q1 24 | $23.5M | — | ||
| Q4 23 | $-9.5M | — | ||
| Q3 23 | $35.5M | — |
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q2 25 | — | -22.1% | ||
| Q1 25 | -106.0% | — | ||
| Q4 24 | -15.7% | — | ||
| Q3 24 | -110.7% | — | ||
| Q2 24 | 56.4% | — | ||
| Q1 24 | 35.7% | — | ||
| Q4 23 | 11.7% | — | ||
| Q3 23 | 32.0% | — |
| Q2 25 | — | -24.7% | ||
| Q1 25 | -84.4% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | -71.7% | — | ||
| Q2 24 | 58.1% | — | ||
| Q1 24 | 39.7% | — | ||
| Q4 23 | -22.8% | — | ||
| Q3 23 | 81.1% | — |
| Q2 25 | — | $-0.55 | ||
| Q1 25 | $-0.42 | — | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $1.55 | — | ||
| Q1 24 | $0.68 | — | ||
| Q4 23 | $-0.23 | — | ||
| Q3 23 | $1.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $67.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $417.3M | $19.0M |
| Total Assets | $486.5M | $21.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q1 25 | $67.8M | — | ||
| Q4 24 | $101.2M | — | ||
| Q3 24 | $78.0M | — | ||
| Q2 24 | $185.3M | — | ||
| Q1 24 | $68.4M | — | ||
| Q4 23 | $67.6M | — | ||
| Q3 23 | $51.9M | — |
| Q2 25 | — | $19.0M | ||
| Q1 25 | $417.3M | — | ||
| Q4 24 | $428.7M | — | ||
| Q3 24 | $422.4M | — | ||
| Q2 24 | $429.9M | — | ||
| Q1 24 | $269.4M | — | ||
| Q4 23 | $242.4M | — | ||
| Q3 23 | $246.7M | — |
| Q2 25 | — | $21.0M | ||
| Q1 25 | $486.5M | — | ||
| Q4 24 | $526.3M | — | ||
| Q3 24 | $554.6M | — | ||
| Q2 24 | $582.0M | — | ||
| Q1 24 | $510.8M | — | ||
| Q4 23 | $469.2M | — | ||
| Q3 23 | $485.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.5M | $-1.2M |
| Free Cash FlowOCF − Capex | $-39.7M | — |
| FCF MarginFCF / Revenue | -192.9% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-58.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-1.2M | ||
| Q1 25 | $-38.5M | — | ||
| Q4 24 | $-31.6M | — | ||
| Q3 24 | $-24.3M | — | ||
| Q2 24 | $39.8M | — | ||
| Q1 24 | $-25.5M | — | ||
| Q4 23 | $-4.0M | — | ||
| Q3 23 | $-24.5M | — |
| Q2 25 | — | — | ||
| Q1 25 | $-39.7M | — | ||
| Q4 24 | $-32.2M | — | ||
| Q3 24 | $-24.9M | — | ||
| Q2 24 | $38.8M | — | ||
| Q1 24 | $-26.4M | — | ||
| Q4 23 | $-5.0M | — | ||
| Q3 23 | $-25.9M | — |
| Q2 25 | — | — | ||
| Q1 25 | -192.9% | — | ||
| Q4 24 | -86.2% | — | ||
| Q3 24 | -127.3% | — | ||
| Q2 24 | 41.0% | — | ||
| Q1 24 | -44.6% | — | ||
| Q4 23 | -11.9% | — | ||
| Q3 23 | -59.3% | — |
| Q2 25 | — | — | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.4% | — | ||
| Q4 23 | 2.3% | — | ||
| Q3 23 | 3.3% | — |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -27.94× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.72× | — | ||
| Q1 24 | -1.09× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
